This funding opportunity supports multidisciplinary collaborative research efforts aimed at advancing glioblastoma research, with a focus on IDH-wild type glioblastoma as defined by the World Health Organization's 2021 classification. The program seeks innovative approaches to improve patient outcomes and quality of life. Research proposals must address at least one of the program’s areas of emphasis: developing new or improved treatments, exploring novel methods for disease detection and monitoring, and expanding glioblastoma-related research resources.

The Transformative Consortium Award is structured to fund one consortium with 4 to 5 integrated projects centered on a shared hypothesis. The Consortium Director and up to four additional Project Team Principal Investigators will collaborate to deliver innovative solutions that advance the field of glioblastoma research. The consortium must include consumer advocates and foster multidisciplinary collaboration across institutions. Proposed projects may encompass clinical trials, translational research, or resource development.

The total award amount is up to $9.09 million for a maximum performance period of four years. Funds may cover travel for annual meetings, consortium workshops, personnel costs, and research-related expenses. Eligible applicants include both extramural and intramural organizations, such as academic institutions, non-profits, and Department of Defense entities. Cost-sharing is not required. Each Principal Investigator (PI) must demonstrate expertise in their respective project and meet minimum effort requirements.

Applications involve a two-step submission process via the eBRAP system: a pre-application due by December 23, 2024, and a full application due by January 13, 2025. All applications must comply with submission and formatting requirements to avoid administrative withdrawal. Applicants should address eligibility, include detailed plans for data sharing and collaboration, and outline post-award transition strategies for their research outcomes.

Review criteria emphasize scientific merit, alignment with program priorities, collaborative potential, and the feasibility of achieving transformative impacts on glioblastoma care. Award decisions will consider both peer-review scores and programmatic relevance to Defense Health Program objectives. Successful applicants will be notified by September 30, 2025, with funding subject to final reviews and approvals.

For further assistance or clarification, applicants can contact the eBRAP Help Desk or the Grants.gov Contact Center. Full details are provided in the program announcement document and the General Application Instructions available on the eBRAP website.